False-negative results of breast core needle biopsies – retrospective analysis of 988 biopsies (2024)

  • Journal List
  • Pol J Radiol
  • v.76(1); Jan-Mar 2011
  • PMC3389906

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

False-negative results of breast core needle biopsies – retrospective analysis of 988 biopsies (1)

Polish Journal of Radiology

Pol J Radiol. 2011 Jan-Mar; 76(1): 25–29.

PMCID: PMC3389906

PMID: 22802813

Marek Boba,1 Urszula Kołtun,1 Barbara Bobek-Billewicz,1 Ewa Chmielik,2 Bartosz Eksner,1 and Tomasz Olejnik1

Author information Article notes Copyright and License information PMC Disclaimer

Summary

Background:

Breast cancer is the most common malignant neoplasm and the most common cause of death among women. The core needle biopsy is becoming a universal practice in diagnosing breast lesions suspected of malignancy.

Unfortunately, breast core needle biopsies also bear the risk of having false-negative results.

Material/Methods:

988 core needle breast biopsies were performed at the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, between 01 March 2006 and 29 February 2008. Malignant lesions were diagnosed in 426/988 (43.12%) cases, atypical hyperplasia in 69/988 (6.98%), and benign lesions in 493/988 (49.90%) cases.

Results:

Twenty-two out of 988 biopsies (2.23%) were found to be false negative. Histopathological assessment of tissue specimens was repeated in these cases. In 14/22 (64%) cases, the previous diagnosis of a benign lesion was changed. In 8/22 (36%) cases, the diagnosis of a benign lesion was confirmed. False-negative rate was calculated at 2.2%. The rate of false-negative diagnoses resulting from a radiological mistake was estimated at 36%. The rate of false-negative diagnoses, resulting from histopathological assessment, was 64%. False-negative results caused by a radiological error comprised 1.5% of all histopathologically diagnosed cancers and atypias (sensitivity of 98.5%). There were no false-positive results in our material - the specificity of the method was 100%.

Conclusions:

Histopathological interpretation is a substantial cause of false-negative results of breast core needle biopsy. Thus, in case of a radiological-histopathological divergence, histopathological analysis of biopsy specimens should be repeated. The main radiological causes of false-negative results of breast core needle biopsy are as follows: sampling from an inappropriate site and histopathological non-hom*ogeneity of cancer infiltration.

Keywords: breast cancer, core needle biopsy, false negative results

Background

Breast cancer is the most frequent malignancy and the most common cause of death in women. In highly developed countries, the incidence of breast cancer is increasing. Poland belongs to countries with a medium incidence rate. Epidemiological data of 2006 report 13322 new cases (standardised incidence coefficient of 44.2) [1]. Despite advances in the diagnostics and treatment of breast cancer, it was impossible to achieve a decrease in the number of deaths in Poland – the number is still on the rise, and in 2006 it was 5212 (standardised death coefficient of 14.8) [1].

Advances in the field of imaging led to the development of methods that allow for breast cancer detection in a clinically silent period. This significantly improves the prognosis.

A basic method of radiological diagnostics in breast cancer is X-ray mammography. It has become a tool used in screening thanks (inter alia) to its high sensitivity, of 80–100% [24].

Unfortunately, the specificity of this method is substantially lower, which requires using other diagnostic methods (utrasonography, sonoelastography, MR mammography) and cytological or histopathological verification of suspicious lesions. Approximately 75% (on average) of lesions qualified for microscopic verification on the basis of mammography turn out to be benign [5].

Core needle biopsy is an increasingly more common method used in the diagnostics of breast lesions suspected of malignancy. This is the main alternative to a reference surgical biopsy [68] which is more expensive, carries an additional risk connected with the operation and causes a higher mental stress for the patient. Surgical biopsy is not free of false-negative results either. According to one of the studies, their rate was 2.5 [9].

Core needle biopsy allows for sampling of tissue material which can help in exact identification of the cancer type and grade. Moreover, it does not require patient’s hospitalisation, it is performed under local anaesthesia and is minimally invasive. The currently used biopsy systems allow for a precise identification of the site of material sampling. Unfortunately, core needle biopsy carries also a risk of false-negative results.

Material and Medods

At the Maria Skłodowska–Curie Memorial Cancer Center And Institute Of Oncology, Gliwice Branch, 988 core needle biopsies were performed between 01 March 2006 and 29 February 2008. The examined women were aged from 25 to 85 years (mean age of 55.1 years). They were qualified for core needle biopsy on the basis of mammography and ultrasonography.

Malignant lesions were found in 426/988 cases (43.12%), atypical ductal/lobular hyperplasia in 69/988 cases (6.98%) [in 13/69 cases of atypical hyperplasia (18.84%), cancer was diagnosed after tumorectomy], and benign lesions in 493/988 cases (49.90%).

Results of 22/988 biopsies (2.23%) which showed benign lesions were found to be false-negative because further diagnostic procedures performed within maximum 3 months revealed a malignancy at the site qualified for biopsy on the basis of mammographic or ultrasound results. Cases in which the biopsy revealed atypia and further diagnostic procedures showed cancer, were treated as underestimated positive results and excluded from the analysis of false-negative results.

The time from the moment of false-negative biopsy till the onset of cancer treatment ranged from 1 month to 4 months (3.2 months on average).

Stereotactic core needle biopsies were performed with the use of Lorad Multicare Platinum (Hologic) table. Depending on the type of lesion, a different biopsy gun was used: Magnum (Bard) for automatic biopsy with 14 G needle if the mammography showed mammography showed a suspicious density/module, or a vacuum-assisted core needle biopsy set, Vacora (Bard) with 10 G needle, in case of microcalcifications.

During procedure, X-rays were taken to: 1. locate the lesion (3 mammograms), 2. check the location of the needle in the lesion (2 mammograms), 3. monitor the lesion after sampling (2 mammograms), and in case of sampling of microcalcifications also to: 4. check the location of the marker that was left at the site of previous sampling (2 mammograms).

US-guided biopsy used a 13-MHz linear probe. Procedure was carried out with the use of automatic biopsy gun Magnum (Bard) with 14G needle.

A typical tissue section collected during vacuum-assisted biopsy weighed approx. 150–170 mg and was from 10 to 20 mm long. At least 12 and maximally 20 samples were collected. The section obtained with the automatic biopsy gun was much smaller, weighed about 20 mg and its length depended on the position of the gun – from 15 to 22 mm. At least four of them and maximally 12 such samples were collected (Table 1).

Tabela 1.

The analysed biopsies according to the biopsy system and the guidance used.

Vacora (MMG)Magnum (MMG)Magnum (USS)
Number of performed biopsies326 (33%)468 (47.4%)194 (19.6%)

Open in a separate window

The collected material was fixed in a 10% buffered formalin solution and sent for microscopic evaluation.

Results

From among 988 biopsies, 22 (2.23%) were found false-negative. They were histopathologically reexamined. Serial sectioning of paraffin blocks was performed. The blocks included the sampled tissues. Next, primary and additional samples were assessed.

In 14/22 cases (64%), a previous histopathological diagnosis of benign lesion was changed:

  • In 2/14 cases, cancer was found – Ca lobulare infiltrans, DCIS (previously, no cancer cells were found) and Papilloma intraductale.

  • In 12/14 cases, atypia was found, with indications to remove the lesion.

In 6/12 cases, flat epithelial atypia was diagnosed (primary diagnosis: adenosis (2 cases), fibrous lesion (1 case), fibrocystic lesion (1 case), fibrosclerosis (1 case), and inflammatory infiltrations (1 case)):

  • In 2/12 cases – Atypical ductal hyperplasia (primarily: fibrous lesions and fibrous lesion).

  • In 3/12 cases – Flat epithelial atypia and atypical ductal hyperplasia (primarily: Adenosis sclerosans in 2 cases and fibrous lesion in 1 case).

  • In 1/12 case – Radial scar. Atypical apocrine metaplasia in adenosis (primarily: only adenosis sclerosans).

In 8/22 cases (36%), a repeated histopathological examination confirmed the primary result of no cancer cells in the sample or the presence of benign lesion (in 6 cases, columnar cell changes were found as well) (Table 2).

Tabela 2.

False-negative biopsy results caused by a radiological mistake.

AgeFirst symptomsBI- RADSACRType of lesionSize of lesionType of biopsyFirst histopathological diagnosisDiagnosis following repeated histopathological evaluationType of the next biopsyFinal histopathological diagnosis – cancer typeTime to treatment onset (months)
38Orange peel skin44MCa5 cmVacora mmgLaesio fibrosocysticaColumnar cell changes (CCC). MastitisFNABDuctal4
48Nodule63AbMagnum mmgLaesio fibrosaCCC. Fibrosclerosis. Fat necrosis with fibrosisFNABDuctalTreated
48MMG without indications54Dc+MC4×3.5 cmMagnum mmgScarce material: a few ducts, sclerosing stroma, fragment of muscle tissueCCC. Muscle tissueVacoraDCIS4
68Screening51D1.5 cmMagnum mmgLaesio fibrosocysticaCCH. CCC. Scarce materialSurgicalDuctal3
55Follow-up examination31D0.8 cmMagnum usgLaesio fibrosaFA. CCC.SurgicalDuctal3
61Follow-up examination52D+MC3 cmMagnum mmgGranulomatous mastitisGranulomatous mastitis. MCMagnumDuctal following from inflammation4
49Presented with FNAB result62D2×2 cmMagnum mmgFibrosclerosis. Adenosis sclerosansCCC. CCH. HD. Adenosis sclerosans. FibrosisSurgicalDuctalTreated
74Nodule31D3.4×2.3×4 cmMagnum usgFragments of adipose tissue without calcifications. Scarce materialScarce materialSurgicalDuctal1

Open in a separate window

aMicrocalcifications;

basymmetry;

cdensification.

False-negative results constituted 2.2% of all biopsy results. As much as 36% of them resulted from the course of the radiological procedure, and 64% appeared during histopathological evaluation. False-negative results caused by a radiological failure constituted 0.8% of all biopsy results and 1.5% of histopathologically diagnosed cancers and atypias (sensitivity of 98.5%). In the analysed material, there were no false-positive results, and the specificity of the method amounted to 100% (Tables 3, ​,44).

Tabela 3.

False-negative results caused by radiological procedure, presented according to the biopsy system and the guidance used.

Vacora (MMG)Magnum (MMG)Magnum (USS)
False-negative results1 (12.5%)5 (62.5%)2 (25%)
False-negative results/number of procedures1/326 (0.3%)5/468 (1.07%)2/194 (1.03%)
Sensitivity of the method99.2%97.9%98.6%
98.3%

Open in a separate window

Tabela 4.

Causes of radiological errors.

Sampling at a wrong site (the lesion was not hit correctly)Sampling at the correct site – histopathological heterogeneity of the lesion
Number of false-negative biopsies71

Open in a separate window

Discussion

False-negative result of the core needle biopsy can lead to a delay in diagnosis and treatment of breast cancer [1012]. In the analysed material, i.e. 988 biopsies, they constituted 2.23% (22 lesions).

After an additional histopathological evaluation, the diagnosis was changed in 64% of these patients (14/22) and remained unchanged in 8/22 patients (36%).

Thus, histopathological evaluation of the sampled material could not lead to a right diagnosis in 0.8% of all biopsies and 1.5% of histopathologically diagnosed cancers and atypias. This result falls in the range reported in the literature – rate of false-negative results ranges from 0% to 6% [6,7,8,11,1319].

In the studied group of patients, it was striking that as much as 64% of false-negative results were obtained during histopathological evaluation, which was frequently considered to be unquestionable and definitive. These data confirm the significance of consensus between the radiological and histopathological results. In case of no conformity between the radiological image and histopathological results, it should be aimed to analyse the sampled material one more time, and then to repeat the radiological or surgical biopsy – this opinion is in accordance with opinions of other authors [8,11,12].

In our material, the highest sensitivity (99.2%) was found in case of stereotactic vacuum-assisted biopsy. When comparing core needle biopsies performed with an automatic gun, US-guided biopsy was found slightly more sensitive (98.6%). The sensitivity of stereotactic biopsy was 97.9%. In the studies by other authors, the sensitivity of vacuum-assisted biopsies was similar: in case of US-guided core needle biopsies, it was from 92% [20] to 100% [21], and in case of stereotactic biopsies – over 91% [11].

The radiological causes of false-negative results of core needle biopsies in the analysed material were divided into 2 groups:

  1. Sampling of the material from a wrong site (the lesion was not hit correctly)

    The most common causes include:

    • Selection of a wrong imaging method guiding the course of the biopsy. Most of the sampled lesions are guided by US [11] which, in comparison to stereotactic guidance, shows many advantages, allowing for a better control of the sampling process [11]. US-guided biopsies are performed in real time [11]; they allow for a direct visualisation of the needle [11,12], the time of the procedure is shorter [11,12,22], the method is more comfortable for the patient [11,12,22], and does not expose the patient to ionising radiation [11,12]. In the analysed material, 3/8 of false-negative cases would probably be better monitored under US than under stereotactic guidance (due to the characteristics of the lesions).

    • Choice of a wrong biopsy system. The precision of biopsies performed with automatic guns is lower for microcalcifications than for tumours [6,10,11,21]. It was probably the cause of one false-negative result.

    • No monitoring of needle location in US-guided biopsies in the orthogonal position of the probe [12], disadvantageous location of the lesion (deeply, next to the chest wall [11,12]), poor visualisation of the lesion or needle [12] due to e.g. wrong contrast parameters, haematoma, local anaesthesia at the site of the lesion. In our material, these were the probable causes of 3 false-negative results.

  2. Histopathological nonhom*ogeneity of the lesion

Breast cancer may include not only neoplastic cells but also regions of fibrosis, necrosis, typical and atypical intraductal or intralobular proliferations or inflammatory components. This histopathological heterogeneity of the lesion (coexistence of cancer and inflammation), despite collection of 10 sections, was the probable cause of one of our false-negative results. This problem was probably also the cause of underestimation of biopsy results (i.e. situation in which atypia was diagnosed, and then, intraoperatively, cancer was found). Cases in which atypia was found in the first or the second stage of histopathological evaluation, and then, intraoperatively, cancer was diagnosed, constituted 10.4% of all diagnosed cancers. Underestimation has also been reported by many authors [7,10,11,12]. It’s frequency is close to 12.8% in stereotactic biopsies [12].

Conclusions

Histopathological interpretation is a significant cause of false-negative results of core needle biopsies of the breast. In case of divergence between radiological and histopathological findings, the material sampled during biopsy should be reanalysed.

The main radiological causes of false-negative results of core needle biopsy of the breast include sampling at a wrong site, and histological heterogeneity of the tumour.

References:

1. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2006 roku. Centrum Onkologii – Instytut. 2008;65:98. [in Polish] [Google Scholar]

2. Kacl GM, Liu P, Debatin JF, et al. Detection of breast cancer with conventional mammography and contrast-enhanced MR imaging. Eur Radiol. 1998;8(2):194–200. [PubMed] [Google Scholar]

3. Howard M, Agarwal G, Lytwyn A. Accuracy of self-reports of Pap and mammography screening compared to medical record: a meta-analysis. Cancer Causes Control. 2009;20(1):1–13. [PubMed] [Google Scholar]

4. Bukhari MH, Akhtar ZM. Comparison of accuracy of diagnostic modalities for evaluation of breast cancer with review of literature. Diagn Cytopathol. 2009;37(6):416–24. [PubMed] [Google Scholar]

5. Knutzen AM, Gisvold JJ. Likelihood of malignant disease for various categories of mammographically detected, nonpalpable breast lesions. Mayo Clin Proc. 1993;68(5):454–60. [PubMed] [Google Scholar]

6. Parker SH, Burbank F, Jackman RJ, et al. Percutaneous large-core breast biopsy: a multi-institutional study. Radiology. 1994;193:359–64. [PubMed] [Google Scholar]

7. Brenner RJ, Bassett LW, Fajardo LL, et al. Stereotactic-needle breast biopsy: a multi-institutional prospective trial. Radiology. 2001;218:866–72. [PubMed] [Google Scholar]

8. Sauer G, Deissler H, Strunz K, et al. Ultrasound-guided large-core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumour classification. Br J Canc. 2005;92:231–35. [PMC free article] [PubMed] [Google Scholar]

9. Marzoni FA. Needle-localised breast biopsy: why do we fail? Radiology. 1997;204:677–84. [PubMed] [Google Scholar]

10. Pijnappel RM, van den Donk M, Holland R, et al. Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions. Br J Cancer. 2004;90(3):595–600. [PMC free article] [PubMed] [Google Scholar]

11. Dillon MF, Hill AD, Quinn CM, et al. The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg. 2005;242(5):701–7. [PMC free article] [PubMed] [Google Scholar]

12. Youk JH, Kim EK, Kim M, et al. Missed breast cancers at US-guided core needle biopsy: how to reduce them. Radiographics. 2007;27(1):79–94. [PubMed] [Google Scholar]

13. Liberman L, Feng TL, Dershaw DD, et al. US-guided Core Breast Biopsy: Use and Cost-effectiveness. Radiology. 1998;208:717–23. [PubMed] [Google Scholar]

14. Smith DN, Rosenfield Darling ML, Meyer JE, et al. The utility of ultrasonographically guided large-core needle biopsy: results from 500 consecutive breast biopsies. J Ultrasound Med. 2001;20(1):43–49. [PubMed] [Google Scholar]

15. Schoonjans JM, Brem RF. Fourteen-gauge ultrasonographically guided large-core needle biopsy of breast masses. J Ultrasound Med. 2001;20(9):967–72. [PubMed] [Google Scholar]

16. Wu YC, Chen DR, Kuo SJ. Personal experience of ultrasound-guided 14-gauge core biopsy of breast tumor. Eur J Surg Oncol. 2006;32(7):715–18. [PubMed] [Google Scholar]

17. Memarsadeghi M, Pfarl G, Riedl C, et al. Value of 14-gauge ultrasound-guided large-core needle biopsy of breast lesions: own results in comparison with the literature. Rofo. 2003;175(3):374–80. [PubMed] [Google Scholar]

18. Crystal P, Koretz M, Shcharynsky S, et al. Accuracy of sonographically guided 14-gauge core-needle biopsy: results of 715 consecutive breast biopsies with at least two-year follow-up of benign lesions. J Clin Ultrasound. 2005;33(2):47–52. [PubMed] [Google Scholar]

19. Buchberger W, Niehoff A, Obrist P, et al. Sonographically guided core needle biopsy of the breast: technique, accuracy and indications. Radiologe. 2002;42(1):25–32. [PubMed] [Google Scholar]

20. Mainiero MB, Koelliker SL, Lazarus E, et al. Ultrasound-guided large-core needle biopsy of the breast: frequency and results of repeat biopsy. J Women Imaging. 2002;4:52–7. [Google Scholar]

21. Parker SH, Jobe WE, Dennis MA, et al. Usguided automated large-core breast biopsy. Radiology. 1993;187:507–11. [PubMed] [Google Scholar]

22. Mainierio MB, Gareen IF, Bird CE, et al. Preferential use of sonographically guided biopsy to minimise patient discomfort and procedure time in a percutaneous image guided breast biopsy program. J Ultrasound Med. 2002;21:1221–26. [PubMed] [Google Scholar]

Articles from Polish Journal of Radiology are provided here courtesy of Termedia Publishing

False-negative results of breast core needle biopsies – retrospective analysis of 988 biopsies (2024)

FAQs

False-negative results of breast core needle biopsies – retrospective analysis of 988 biopsies? ›

Twenty-two out of 988 biopsies (2.23%) were found to be false negative. Histopathological assessment of tissue specimens was repeated in these cases. In 14/22 (64%) cases, the previous diagnosis of a benign lesion was changed.

What is the false negative rate for core needle biopsy? ›

Core needle biopsies tend to have a lower false-negative rate compared to FNA, with studies reporting rates between 1% and 10%. The use of imaging guidance during the procedure, such as ultrasound or mammography, can help improve the accuracy of the biopsy and further reduce the risk of false-negative results.

Can a breast core biopsy be wrong? ›

Although tests aren't 100% accurate all the time, receiving a wrong answer from a cancer biopsy – called a false positive or a false negative – can be especially distressing. While data are limited, an incorrect biopsy result generally is thought to occur in 1 to 2% of surgical pathology cases.

What causes a false negative biopsy? ›

Causes of False-Negative Diagnosis

False-negative diagnoses may result from technical difficulties, sampling error, or interpretive errors. For a cytopathologist, offering a diagnosis based on hypocellular samples is a common cause of false diagnosis.

What is the diagnostic accuracy of a core needle biopsy? ›

Conclusions: Core needle biopsy is a highly accurate diagnostic technique with an accuracy of 90% for separation of benign from malignant lesions. The percentage of non-diagnostic cases is low (3.4%).

What is the most common cause of false-negative FNA? ›

In fact, in some studies, the most common cause of a false-negative diagnosis by FNA is the presence of an unsampled microcarcinoma in the setting of an adenomatous goiter [15, 28].

Can a biopsy show a false-negative? ›

Biopsies are a very accurate way to detect abnormal cells or other changes in your body that may be signs of issues. That said, studies suggest false-negative results do happen.

How often are core needle biopsies wrong? ›

Drawbacks of core needle biopsy

This is called a false negative result and delays diagnosis. For abnormal findings that can't be felt (can only be seen on a mammogram or other imaging test), false negative results occur in up to 4% of image-guided core needle biopsies [5-7].

What percent of core biopsies are cancerous? ›

Suspicious mammographic findings may require a biopsy for diagnosis. More than 1 million women have breast biopsies each year in the United States. About 20 percent of these biopsies yield a diagnosis of breast cancer.

What are the diagnostic pitfalls in needle core biopsy of the breast? ›

One of the pitfalls in core biopsy diagnosis is to mistake the diagnosis of malignant conditions as benign.

Can a core needle biopsy be wrong? ›

The currently used biopsy systems allow for a precise identification of the site of material sampling. Unfortunately, core needle biopsy carries also a risk of false-negative results.

How often are biopsies misdiagnosed? ›

Biopsy specimens are examined by pathologists, who look at the tissue sample under a microscope in order to determine if it is cancerous. It has been estimated that 1 in every 71 biopsies is misdiagnosed as cancerous when it was not, and 1 out of every 5 cancer cases was misclassified.

How many breast biopsies come back negative? ›

A breast biopsy is a common procedure that healthcare providers use to determine if a suspicious area in your breast could be cancer, though approximately 80% of breast biopsy results are not cancer.

What is the success rate of a core needle biopsy? ›

In a report by Chang et al., the success of biopsies taken with 11-G needles was 84.6% compared to 63.6% with smaller diameter needles [8]. One could advocate for the use of needles with larger diameters, which may decrease the number of biopsy attempts needed.

What is the difference between a core biopsy and a needle biopsy? ›

Core-needle biopsy makes it possible to establish a final diagnosis more frequently than fine-needle biopsy, both in the case of benign and malignant lesions. It delivers more information about the nature of a tumor (mutation of HER-2, estrogen and progesterone receptors and Ki-67 index).

What is the specificity of a core needle biopsy? ›

CNB achieved histological accuracy for subtype diagnosis in 87% of cases compared to 89% from incisional biopsy. As confirmed by pathology on the definitive specimen, tumor grading was correct in 87% of CNB specimens compared to 84% of incisional biopsy specimens.

How accurate is a core needle biopsy for lymph nodes? ›

5). The overall sensitivity of the US-CNB for the detection of ALNs metastases from BC was 0.90 (95% CI [confidence interval] 0.87‒0.91; p = 0.00). Pooled studies were heterogenous (I2 = 57.30%). The overall specificity of the US-CNB for the detection of ALNs metastases from BC was 0.99 (95% CI 0.98‒1.00; p = 0.62).

What percentage of breast needle biopsies are positive? ›

According to research in JAMA Internal Medicine, between 20% to 42% of breast biopsies reveal a breast cancer diagnosis, depending on age.

How accurate are core needle biopsies for lymphoma? ›

Core needle biopsy was reported to be benign in 11 of 60 patients and 7 of 11 patients were misdiagnosed as having a lymphoma in this cohort. However, publications from single institutions like our study show a conclusive result for the diagnosis of lymphoma by CNB specimens in over 80%-90% of the cases.

Top Articles
Latest Posts
Article information

Author: Arline Emard IV

Last Updated:

Views: 6310

Rating: 4.1 / 5 (52 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Arline Emard IV

Birthday: 1996-07-10

Address: 8912 Hintz Shore, West Louie, AZ 69363-0747

Phone: +13454700762376

Job: Administration Technician

Hobby: Paintball, Horseback riding, Cycling, Running, Macrame, Playing musical instruments, Soapmaking

Introduction: My name is Arline Emard IV, I am a cheerful, gorgeous, colorful, joyous, excited, super, inquisitive person who loves writing and wants to share my knowledge and understanding with you.